Drug Database
CL

clindamycin (ResiDerm A / Zindaclin)

✓ Approved

Teva Pharmaceutical Industries Ltd. · 小分子 · 小分子

什么是 clindamycin?

clindamycin 是一种小分子,由Teva Pharmaceutical Industries Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名ResiDerm A, Zindaclin
公司Teva Pharmaceutical Industries Ltd.
药物类别小分子
给药途径Topical
状态Approved

治疗适应症

clindamycin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersAcne✓ Approved

相关研究文献

PubMedZhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]2026-11-16

[Pathogenic characterizations of two M1UK-lineage group A streptococcus strains in Guangdong Province].

Hu Y Y, Li Z C ZC, Liu M Z MZ, Zhang C C et al.

This study conducted antimicrobial susceptibility tests and whole-genome sequencing of two M1UK-lineage group A streptococcus strains isolated in Dongguan and Guangzhou,Guangdong Province. The genome sequences of two isolates are approximately 1.8 Mb,emm1/ST28. The strains are sensitive to erythromycin, clindamycin, tetracycline and 12 other Antimicrobial drugs.They carry resistance genes lmrP and mefE while possessing multiple virulence genes. The genomes hold 27 single nucleotide polymorphisms unique to the M1UK lineage and are clustered with the international M1UK lineage GAS strain.

PMID 43035298
阅读全文 →
PubMedBMC infectious diseases2026-11-16

Nasal colonization and antimicrobial susceptibility profile of Staphylococcus aureus among healthcare workers at selected health institutions in Bahir Dar, Northwest Ethiopia.

Belete Melkamu M, Admas Alemale A, Melese Addisu A

Staphylococcus aureus (S. aureus) is a leading cause of healthcare- and community-acquired infections, ranging from mild skin conditions to severe systemic disease. Healthcare workers are frequently colonized, serving as potential reservoirs for transmission to patients, attendants, and colleagues. Nasal screening is a key strategy in controlling Methicillin-Resistant Staphylococcus aureus (MRSA), yet data remain scarce in the study area. The aim of this study was to determine the prevalence of nasal colonization and the antimicrobial susceptibility profile of S. aureus among healthcare workers in selected health institutions in Bahir Dar, Northwest Ethiopia. An institution-based cross-sectional study was conducted from April to July 2023 among 249 Healthcare workers. A systematic random sampling was employed to include study participants. The nasal samples were collected and processed following standard bacteriological procedures. Antimicrobial susceptibility testing was performed using a disk diffusion method on Mueller Hinton Agar. Data were coded, entered, and analyzed using the SPSS version 27 statistical package. Logistic regression analysis was done to identify factors associated with nasal colonization by S. aureus and p < 0.05 was considered statistically significant. Colonization with S. aureus and MRSA was 15.7% (39/249) and 3.2% (8/249); respectively. From the S. aureus isolates, 20.5% (8/39) were MRSA. Of the S. aureus isolates, 82.1% (32/39) were resistant to Penicillin. About 30.8% isolates were multi-drug resistant (MDR). On the other hand, 89.7% (35/39) of the isolates were sensitive to Clindamycin, 89.7% (35/39) to Chloramphenicol, and 87.2% (34/39) to Ciprofloxacin. Infrequent hand-washing habits after patient contact (AOR = 6.770, 95% CI: 2.054-22.311; p = 0.002), Working in health center (AOR = 4.125, 95% CI: 1.390-12.245; p = 0.011) and frequent nose-picking habits (AOR = 3.378, 95% CI: 1.276-8.949; p = 0.014) were significantly associated with nasal colonization with S. aureus. The nasal colonization rate of S. aureus and MRSA was lower than previous studies in the Amhara region. The isolates were relatively susceptible to Clindamycin, Chloramphenicol, and Ciprofloxacin. Infrequent hand-washing habits after patient contact, working in the health center and frequent nose-picking habits were significantly associated with nasal colonization with S. aureus. Hygienic activities should be practiced to prevent colonization and cross-transmission.

PMID 43035679
阅读全文 →
PubMedThe Journal of surgical research2026-11-16

Antimicrobial Management of Surgical Necrotizing Enterocolitis: A Multi-Institutional Analysis.

Campwala Insiyah I, Patwardhan Utsav M UM, Gollin Gerald G, Yanowitz Toby D TD et al.

Evidence-based antimicrobial regimens are lacking for surgical necrotizing enterocolitis. We evaluated the association between antimicrobial practices and outcomes. We conducted a retrospective cohort analysis of infants with surgical necrotizing enterocolitis (2010-2019) at ten children's hospitals. Demographics, antimicrobial choice, and postoperative outcomes were assessed using multivariable regression. Among 306 neonates (median gestational age 26 wk [interquartile range 25-29], birth weight 850 g [680-1100], age at diagnosis 8.5 wk [3-21]), 15 antimicrobials were used in 94 initial regimens. Postoperatively, 15 were administered in 107 regimens. Pre- and postoperative regimens differed in 67%. The most frequently used antibiotics were ampicillin, clindamycin, gentamicin, and vancomycin. Antifungals were often given to those with lower weight at diagnosis. 34% died during the index admission. No initial antimicrobial agent was associated with mortality. Excluding early deaths, patients received a median of 14 d of postoperative antibiotics. The duration of postoperative antibiotics (>7 d versus < 7 d) was not significantly associated with in-hospital mortality (odds ratio 0.86, P = 0.93). Adjusted regression analyses demonstrated no associations between postoperative antimicrobial choice and enteral autonomy, stoma complications, neurodevelopmental impairment, or cholestasis. Antifungal use was associated with higher odds of late mortality (odds ratio 5.22, P = 0.023), likely secondary to underlying illness severity. Antimicrobial management varied widely. No individual antimicrobial agent improved survival; however, binary analysis of antimicrobial exposure limited conclusions. Longer antimicrobial duration was not associated with improved survival. Prospective randomized studies may help define optimal antibiotic management.

PMID 43038844
阅读全文 →
PubMedFolia microbiologica2026-11-16

Bacterial spectrum, age and calendar-quarter distribution, and antimicrobial susceptibility patterns of isolates recovered from respiratory specimens of children hospitalized with community-acquired pneumonia in Chongqing, China: a three-year retrospective study.

Ren Haijun H, Zhang Jing J, Jin Ling L

Community acquired pneumonia (CAP) continues to be an important cause of admission of children in hospitals. This study focused on bacterial isolates from respiratory samples, age distribution and antibiotic resistance patterns of children below seven years admitted with CAP in Chongqing, China from January 2023 to December 2025. Of the 2,988 patients included in the study, 884 (29.59%) were positive for bacterial culture, with 930 isolates. The predominant species were Haemophilus influenzae (43.01%), Moraxella catarrhalis (22.80%), Streptococcus pneumoniae (14.84%), and Staphylococcus aureus (10.32%). The distribution of recovered isolates differed significantly across age groups (P < 0.01). After adjustment for calendar year, overall culture positivity did not differ significantly across quarters (P = 0.085), although a significant quarter-by-year interaction was observed (P = 0.005), indicating that quarterly patterns varied between years. Year-adjusted quarterly associations were also observed for H. influenzae, M. catarrhalis, and S. aureus. Antimicrobial susceptibility testing showed high non-susceptibility to ampicillin (65.25%) and trimethoprim-sulfamethoxazole (62.33%) among H. influenzae isolates, and to erythromycin and clindamycin (99.19% for each) among S. pneumoniae isolates. Oxacillin non-susceptibility was observed in 20.25% of tested S. aureus isolates, while imipenem non-susceptibility was uncommon among tested Escherichia coli and Klebsiella pneumoniae isolates. These findings support continued regional microbiological surveillance and may inform institutional antimicrobial stewardship. Because nasotracheal suction specimens may contain colonizing organisms, culture recovery alone does not establish the bacterial causes of CAP.

PMID 43035568
阅读全文 →
PubMedPolski przeglad chirurgiczny2026-11-16

Antibiotic Prophylaxis in Metabolic and Bariatric Surgery: A Systematic Literature Review.

Lastovetskyi Ilie I, Zalewski Grzegorz G, Powalacz Izabela I, Kęska Mateusz M et al.

Metabolic and bariatric surgery (MBS) is the most effective treatment for obesity, yet obesity increases the risk of perioperative complications, including surgical site infections (SSIs). Although MBS are classified as clean or clean-contaminated, current guidelines recommend antibiotic prophylaxis (AP) for all such operations, despite the lack of clear clinical evidence supporting this approach. To assess the effect of AP on the incidence of surgical site infection (SSI) rate and other postoperative outcomes after metabolic and bariatric procedures. A systematic search used the terms "Bariatric Surgery" and "Antibiotic Prophylaxis," with added queries for SG, RYGB, OAGB, SADI, SASI, and AGB. Eligible designs included randomized trials and observational studies that reported clinical outcomes such as SSI, wound complications, morbidity, or mortality. Reports without original clinical data were excluded. Data were analyzed separately for clean procedures (SG, AGB) and clean-contaminated procedures (RYGB, SADI, SASI). Eight studies met criteria. Only three studies directly compared AP with no prophylaxis in clean and clean- -contaminated operations and found no significant reduction in SSI rates. In clean procedures, available evidence consistently does not support routine antibiotic use. In clean-contaminated procedures, the available results were underpowered. Isolated studies suggested a modest benefit in selected subgroups, yet none reached statistical significance. Vancomycin may be associated with increased infection risk. Ertapenem was associated with lower infection rates compared with ceftriaxone in open gastric bypass. Single retrospective studies linked lowered postoperative weight loss with levofloxacin use and clindamycin with a higher rate of hypertension remission, but this evidence is weak. Current evidence does not provide strong support for routine perioperative AP in all MBS procedures. Current evidence suggests that routine AP may be unnecessary in selected clean procedures such as SG. In clean-contaminated procedures, selective use may be justified for high-risk patients, but additional studies are required to identify this group. When used, prophylaxis should be weight-adjusted, timed appropriately, and repeated intraoperatively when indicated. Currently available evidence does not support the routine use of AP in all MBS procedures for reducing SSI rates. Especially in clean field procedures this prophylaxis might not be justified. In clean-contaminated procedures, selective use may be justified for high-risk patients. The current level of evidence is rather weak and further studies are needed to evaluate both infectious and metabolic endpoints to develop evidence-based AP strategies in metabolic and bariatric surgery.

PMID 43036192
阅读全文 →
PubMedSage open chronic disease2026-11-15

Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives.

Carugno Andrea A, Bighetti Stefano S, Fratton Zeno Z, Bettolini Luca L et al.

Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating inflammatory dermatosis affecting approximately 1% of the population, with a female predominance and substantial psychosocial burden. Clinically, it presents with painful nodules, abscesses, and draining tunnels that often progress to fibrosis and long-term disability. Pathogenesis is multifactorial, encompassing follicular occlusion and rupture, dysbiosis, neutrophil-rich inflammation, and cytokine networks driven by tumor necrosis factor-alpha and interleukin-17 (IL-17), and despite advances, major challenges persist, including phenotypic heterogeneity, diagnostic delays, and the limited durability of monotherapies. This narrative review critically synthesizes evidence on combination strategies in HS following a systematic search of PubMed, Embase, and Cochrane (2009-July 2025), including randomized and nonrandomized trials, cohorts, and case series (⩾10 patients) that evaluated multimodal approaches (antibiotics plus biologics, biologics within surgical pathways, small molecules in combination, laser/light-based therapies, and structured wound care). Outcomes of interest included Hidradenitis Suppurativa Clinical Response, International Hidradenitis Suppurativa Severity Score System (IHS4)/IHS4-55, tunnel resolution, patient-reported measures (Dermatology Life Quality Index), flare frequency, and safety; qualitative synthesis was performed according to Scale for the Assessment of Narrative Review Articles criteria. Antibiotics remain valuable for induction or bridging: clindamycin-rifampicin and multidrug regimens (rifampin-moxifloxacin-metronidazole, ertapenem) yield meaningful but time-limited benefit, optimally used as preparatory steps toward long-term interventions. Biologics form the backbone of durable disease control (adalimumab, secukinumab, bimekizumab), with enhanced outcomes when initiated alongside antibiotics or integrated perioperatively with surgery for tunnel eradication. Among small molecules, Janus kinase inhibitors (e.g., upadacitinib) show promising efficacy; apremilast and IL-36 blockade are exploratory options; sirolimus and conventional immunosuppressants retain niche utility in syndromic or refractory phenotypes. Adjunctive measures, including laser/light therapies, structured wound care, metabolic interventions (notably glucagon-like peptide-1 receptor agonists), smoking cessation, and psychological support, further consolidate disease control, while multidisciplinary care models optimize sequencing, comorbidity management, and recurrence reduction. In conclusion, combination therapy has emerged as the organizing principle of modern HS management: integrating antibiotic induction, biologics for long-term modification, targeted surgery, and adjunctive measures enables deeper and more durable responses. Future priorities include treat-to-target strategies, biomarker-guided selection, antimicrobial stewardship, and pragmatic real-world evaluations to advance toward near-clearance in a broader patient population.

PMID 43034520
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多clindamycin